Over the past 3 decades, eosinophilic esophagitis (EoE) transformed from a little-known condition to a well-characterized disease often encountered in clinical practice. The Index of Severity for EoE (I-SEE) is now available for you to use to help assess EoE patients. Developed by a multidisciplinary team of experts and published in Gastroenterology, the tool is now available as a point-of-care mobile app.
We are also excited to announce a partnership with Target RWE so they can incorporate I-SEE into the TARGET-GASTRO registry. This will allow AGA access to Target RWE’s robust data platform, which abstracts and curates real-world evidence from electronic health records.
Details about I-SEE
- The I-SEE has three domains: (1) symptoms and complications, (2) inflammatory features and (3) fibrostenotic.
- I-SEE can be used at initial diagnosis and then at each subsequent visit, with the recall being only between visits so that the severity can be assessed over time and ultimately (when data supports this step) treatment and monitoring adjusted based on severity.
- As the number of children and adults with EoE increases worldwide, a simple system to assess and track disease activity in a meaningful way in a clinical setting is needed.
- I-SEE is for use in adult and pediatric patients with EoE. It was created by an international team of more than 30 experts in allergy, gastroenterology and pathology.
Now available as an iOS and Android app!
Read more about AGA's partnership with Target RWE
This program was supported by Genzyme Corporation and Bristol Myers Squibb.
